Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 17Burkitt Lymphoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Large B-Cell, Diffuse 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, B-Cell 2Leukemia, Biphenotypic, Acute 2Blast Crisis 2Vasculitis, Central Nervous System 1Stiff-Person Syndrome 1Stage II Prostate Adenocarcinoma 1Rasmussen subacute encephalitis 1Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1Opsoclonus-Myoclonus Syndrome 1Neuromyelitis Optica 1Neoplasms 1Myasthenia Gravis 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myeloid, Accelerated Phase 1Lambert-Eaton Myasthenic Syndrome 1Immunoblastic Lymphadenopathy 1Hormone-Resistant Prostate Cancer 1Enteropathy-Associated T-Cell Lymphoma 1Down Syndrome 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

prednylidene 1deltacortene 1cabazitaxel 1XRP6258 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hormone-Resistant Prostate Cancer × prednylidene × Clear all
NCT02844582 2021-01-25

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

University of California, Davis

Phase 2 Terminated
2 enrolled 5 charts
Genitourinary

Hormone-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡